ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, is delivering process systems to Ology Bioservices Inc. to support their production of critical vaccines and therapeutics for COVID-19. ABEC is providing these systems to Ology Bioservices’ Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) facility in Alachua, Florida.

Ology Bioservices’ MCM ADM is a flexible multi-product facility, utilizing stainless steel and single-use technologies to accelerate the production of vaccines and therapeutic antibodies. As a full-service biologics contract development and manufacturing organization (CDMO), Ology Bio selected ABEC for their ability to deliver customized bioprocess systems for solutions preparation and filtration applications on a fast-track schedule. Complete in-house capabilities and significant global capacity for system and CSR single-use disposable container (DC) manufacturing enable ABEC to rapidly respond to the needs of biopharmaceutical industry leaders, such as Ology.

“Ology Bio’s ADM facility was designed to respond to critical situations, such as the COVID-19 outbreak,” commented Dr. Peter Khoury, president and CEO of Ology Bio. “ABEC’s responsiveness and flexibility supports our efforts to rapidly manufacture high-quality, COVID-19 therapeutics.”

“We are proud to be a part of Ology Bio’s swift response to the COVID-19 crisis,” added Scott Pickering, ABEC president and CEO. “As the industry’s only provider of customized stainless steel and single-use process solutions, ABEC proactively invests in substantial capacity to credibly respond to our customers’ mission-critical needs.”